NCT03293407View on ClinicalTrials.gov

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

October 9, 2019

Study Completion Date

January 20, 2020

Conditions
Hypertension, Pulmonary
Interventions
DRUG

Iloprost (Ventavis, BAYQ6256)

Using Breelib device

DEVICE

Breelib nebulizer

Used for inhalation of Ventavis

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY